0 Phage therapy: two paths to approval
Discover more about the two routes phage therapy could take, the standardized drug approach and the personalized medicine approach, and whether either could make it to the clinic.
Browsing: Basic > Drug Development
0 Pneumonia, ICU patients and potential treatments – an interview with Keith Kaye
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
2 Bacteriophage: alternative medicine or an evidence-based alternative?
Bacteriophage have been touted as the solution for antibiotic resistant microbes, why are they not being used in mainstream medicine?
0 US FDA approves first rapid diagnostic test for Ebola: October’s industry headlines
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and a rapid diagnostic test for…
0 Antibiotic-loaded nanomesh developed for drug delivery
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.
1 A peek behind the paper – Shujuan Sun on using existing antibiotics as antifungals
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
0 CARVER: CRISPR–Cas13 system kills viruses in human cells
A team from the Broad Institute at MIT and Harvard have designed a Cas13–CRISPR construct, termed CARVER, that can detect and kill viruses inside human cells. The flexible CARVER system could be used as a new tool in research and the clinic.
2 Probiotics for the prevention of sepsis – an interview with Pinaki Panigrahi
In this interview we speak to Pinaki Panigrahi about his work using probiotics as a preventative strategy against sepsis in neonates. In addition, he comments on the impact of probiotics for other infections and some of the skepticism surrounding some microbiome research.
0 US FDA warns of serious liver injury linked to hepatitis C drugs: September’s industry headlines
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
0 Identifying novel antifungal proteins from ‘killer yeasts’ – an interview with Paul Rowley
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.
